Remimazolam for Pediatric Procedural Sedation: Results of an Institutional Pilot Program
Open Access
- 13 September 2023
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (18) , 5937
Abstract
Remimazolam, an ultra-short-acting benzodiazepine sedative, was first approved in 2020 in Japan as a general anesthetic for adults. However, its utilization in pediatric settings remains unexplored and, to date, is confined to isolated case reports due to a lack of specific pediatric labeling. The primary objective of our study was to evaluate the safety profile of remimazolam when used for procedural sedation in children following dosages established in adult protocols. Additional parameters, including dosage per kg of body weight, duration of the procedure, efficacy (measured as successful completion of the procedure), the necessity for supplemental medications, and changes in physiological parameters, such as the heart rate (HR) and mean arterial blood pressure (MAP), were assessed. Our study encompassed 48 children with an average age of 7.0 years. The objective Tracking and Reporting Outcomes of Procedural Sedation tool indicated no adverse events. In our cohort, propofol and ketamine were used as adjunctive treatments in 8 and 39 patients, respectively, with successful completion of all procedures. Notable hemodynamic variability was observed, with 88.4% of patients experiencing a ≥20% change (increase or decrease) and 62.8% experiencing a ≥30% change in MAP. Additionally, a ≥20% change in HR was observed in 54.3% of patients, and a ≥30% change was observed in 34.8% of patients. Nevertheless, none of the patients required pharmacological intervention to manage these hemodynamic fluctuations. Our findings suggest that remimazolam, when supplemented with propofol or ketamine, could offer a safe and effective pathway for administering procedural sedation in pediatric populations.Keywords
This publication has 37 references indexed in Scilit:
- Effect of increasing depth of dexmedetomidine and propofol anesthesia on upper airway morphology in children and adolescents with obstructive sleep apneaJournal of Clinical Anesthesia, 2013
- A randomised study of intranasal dexmedetomidine and oral ketamine for premedication in childrenAnaesthesia, 2013
- A Placebo- and Midazolam-Controlled Phase I Single Ascending-Dose Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Remimazolam (CNS 7056)Anesthesia & Analgesia, 2012
- High-dose dexmedetomidine increases the opioid-free interval and decreases opioid requirement after tonsillectomy in childrenCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 2011
- High‐dose dexmedetomidine sedation for pediatric MRIPediatric Anesthesia, 2011
- Acute Hemodynamic Changes After Rapid Intravenous Bolus Dosing of Dexmedetomidine in Pediatric Heart Transplant Patients Undergoing Routine Cardiac CatheterizationAnesthesia & Analgesia, 2010
- Functional Magnetic Resonance Imaging (fMRI) in Children Sedated With Propofol or MidazolamJournal of Neurosurgical Anesthesiology, 2009
- High dose dexmedetomidine as the sole sedative for pediatric MRIPediatric Anesthesia, 2008
- Sedation and Anesthesia Protocols Used for Magnetic Resonance Imaging Studies in Infants: Provider and Pharmacologic ConsiderationsAnesthesia & Analgesia, 2006
- Dexmedetomidine Premedication Attenuates Ketamine-induced Cardiostimulatory Effects and Postanesthetic DeliriumAnesthesiology, 1995